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Abstract
Background
Malignant melanoma is an aggressive tumor of the skin and seems to be resistant to current
therapeutic approaches. Melanocytic transformation is thought to occur by sequential accu-
mulation of genetic and molecular alterations able to activate the Ras/Raf/MEK/ERK
(MAPK) and/or the PI3K/AKT (AKT) signalling pathways. Specifically, mutations of B-RAF
activate MAPK pathway resulting in cell cycle progression and apoptosis prevention.
According to these findings, MAPK and AKT pathways may represent promising therapeutic
targets for an otherwise devastating disease.
Result
Here we show a computational model able to simulate the main biochemical and metabolic
interactions in the PI3K/AKT and MAPK pathways potentially involved in melanoma devel-
opment. Overall, this computational approach may accelerate the drug discovery process
and encourages the identification of novel pathway activators with consequent develop-
ment of novel antioncogenic compounds to overcome tumor cell resistance to conventional
therapeutic agents. The source code of the various versions of the model are available as
S1 Archive.
Introduction
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways represent fundamental signaling trans-
duction and regulatory networks for the majority of cellular physiological processes, such as
proliferation, differentiation and cell survival.
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These pathways are mostly activated by alterations in Ras, B-RAF, PI3K, and PTEN genes
[1]. Activation of such pathways is responsible of uncontrolled cell proliferation and can con-
tribute to drug resistance. Combination therapies with pharmacological inhibitors of these
pathways may have potential uses for the suppression of cancer cell proliferation and in turn
may be efficacy to revert resistance. Malignant melanoma is a good tumor model to investigate
the activation of RAS/RAF/MEK/ERK and the PI3K/AKT/mTOR pathways as it is frequently
affected by B-RAFV600E mutation that causes the activation of MAPK pathway [2]. It is an
aggressive tumor of the skin with a poor prognosis for patients with advanced disease and it
seems to be resistant to current therapeutic approaches.
Melanocytic transformation is thought to occur by sequential accumulation of genetic and
molecular alterations [3, 4]. Although, the pathogenic mechanisms underlying melanoma
development are still largely unknown, several genes and metabolic pathways have been shown
to carry molecular alterations in melanoma. Melanomas exhibit mutations in the RAS/RAF/
mitogen activated protein kinase (MAPK) pathway. It has been shown that 50% cutaneous
melanomas exhibit B-RAFV600E mutations, which results in an amino acid substitution at posi-
tion 600 in B-RAF, from a valine (V) to a glutamic acid (E). This mutation is known to play a
key role in proliferation and survival of melanoma cells, through activation of the MAPK path-
way [5]. In particular, it occurs within the activation segment of the kinase domain and it
results in an increased activity of the kinase itself. Constitutive activation of the kinase activity
leads to unresponsitivity of negative feedback mechanisms within the MAPK pathway [6].
Additionally, an interaction between the MAPK and the phosphatidylinositide 3-kinase
(PI3K)/AKT pathways has been found in cutaneous melanoma [7]. Interestingly, these studies
suggest that MAPK and AKT pathways are activated in parallel and the evidence that PI3K/
AKT and MAPK/ERK1/2 cascades are interconnected is largely described [8, 9, 10]. There are
multiple cross-talk points between these two pathways, whose coordinated action determines
the cell fate [11]. It is not surprising that the PI3K/AKT and MAPK pathways influence each
other at different stages of signal propagation, both negatively and positively, resulting in
dynamic and complex cross-talk. According to these findings, MAPK and AKT pathways
could represent promising therapeutic targets for an otherwise devastating disease.
Computer simulations and computational modeling are useful to analyze and to increase
knowledge of metabolic pathways and their complex interactions with the aim to understand
the mechanisms of resistance to conventional drug therapy in melanoma [12, 13, 14].
In this work we develop a computational model that simulates both PI3K/AKT and MAPK
pathways and their interactions, in order to analyze the cascade reactions responsible for mela-
noma development. Moreover, we modeled the behavior of the malignant melanoma A375 cell
line, harboring B-RAFV600E mutation, under the treatment of Dabrafenib, a commercial selec-
tive B-RAF inhibitor, recently approved in the treatment of patients with BRAF V600E muta-
tion-positive advanced melanoma [15].
Overall, this model may be used for an in silico lab to study the effects of potential inhibitors
that may improve the response to standard treatments.
Methods
Computational model of MAPK and PI3K/AKT pathways
In order to understand the effects of B-RAF alterations on both RAF-ERK and PI3K-AKT
pathways we started from the model developed by Brown and collaborators [16]. In their work,
the authors presented a computational model of the Epidermal Growth Factor (EGF) and
Nerve Growth Factor (NGF) activated ERK pathway in PC12 cells, containing 13 different pro-
tein species and 16 biochemical reactions. Our model was developed using COPASI (COmplex
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PAthway SImulator), a software for simulation and analysis of biochemical networks and their
dynamics [17]. Our model has considerably expanded the Brown model. It consists of 48 spe-
cies and 48 biochemical reactions.
To include all the entities and their respective interactions useful to the target of this study,
we retrieved all the needed information from KEGG (Kyoto Encyclopedia of Genes and
Genomes) PATHWAY Database [18]. In particular, we focused on the interactions between
two specific pathways: MAPK signaling pathway (Kegg reference: ko04010) and PI3K-AKT
signaling pathway (Kegg reference: hsa04151). We studied the complex behaviour of the most
important protein kinase cascades that involve the epidermal growth factor receptor (EGFR),
phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA), RAC serine/threonine-protein
kinase (AKT) and RAF proto-oncogene serine/threonine-protein kinase (RAF1). This inevita-
bly lead us to consider the other signalling pathways that showed a correlation with the ones
that may induce Dabrafenib resistance phenomena. To this end we also included into the
model Ras signalling pathway (Kegg reference: ko04014) and mTOR signalling pathway (Kegg
reference: ko041150) to investigate any possible mechanisms not observed before.
Relative initial concentrations of entities included in our model were gathered from
GSE22301 available on GEO (Gene Expression Omnibus) dataset (http://www.ncbi.nlm.nih.
gov/geo/) including expression profiling of several melanoma cell line as well as A375 used in
this study. Microarray matrix data were normalized by log transformation using MeV data
analysis tool [19]. Summarizing, we used KEGG database to understand and model the path-
way flow and the GEO dataset to get the A375 cell line expression profiling; moreover, we set
the values of the concentrations of the proteins as found by Brown et al.
The laws that governed the activations/deactivations in the Brown model were based on
Henri-Michaelis-Menten kinetics. This kinetic law is one of the most common model of
enzyme kinetic. Its mathematical form is the following:
VSubstrate=Kmþ Substrate:
It describes the rate of enzymatic reactions, in which “V” represents the maximum rate
reached by the system, while Henri-Michaelis-Menten constant (Km) is the substrate concen-
tration at which the reaction rate is half of V [20].
We slightly modified the classical Henri-Michaelis-Menten law to take into account both the
substrate and the modifier that plays a specific role when we considered reactions that activated
(and/or deactivated) specific proteins. The equation of the modified Henri-Michaelis-Menten is:
KcatSubstrate1Substrate2=ðKmþ Substrate2Þ:
Kcat represents the number of enzymatic reactions catalyzed per second and the equation
includes two types of substrates. Substrate1 stands for the modifier of the reaction, while Sub-
strate2 is the generic substrate. It results more suitable for our purposes because it analyses the
ratio between the reactions of the system and their affinity for the substrate taking in account
the efficiency of the modifier involved.
All the biochemical reactions used in our model can be therefore divided into four main classes:
i) activation/deactivation reactions modeled with a modified Henri-Michaelis-Menten law (for
example Raf1Inactive becomes activated (Raf1Active) through RasActive); ii) reactions that physio-
logically inactivate species, modeled with mass action law (for example C3G deactivation); iii) pro-
teins degradation modeled with mass action law (for example Dabrafenib degradation); iv) proteins
production modeled with irreversible constant flux law (for example, the production of free RTK).
One of the targets of the model was to analyze the dynamics of critical nodes in A375 mela-
noma cell line harboring B-RAFV600E mutation. Therefore, we modeled this cell line as follows:
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i) we introduced the new species bRafMutated with the same initial concentration of bRafInac-
tive of 120000 mmol/ml; ii) we deleted the B-RAF activation by Rap1 as the new species bRaf-
Mutated is not affected by this signalling (the same applies for Ras); iii) we inhibited the
deactivation of B-RAF by Raf1PPtase (as Raf1PPtase does not anymore influence B-RAF); iv)
bRafMutated substitutes the bRafActive species in triggering the Mek activation. The other tar-
get of the model is to use it as an in silico lab to analyze the behavior of specific therapeutic
treatments against melanoma, in particular in its mechanisms of resistance, with the aim to
suggest new strategies that can be used in these circumstances. We, therefore, inserted into the
model the features to reproduce the effect of Dabrafenib inhibitor in the complex dynamics of
the PI3K/AKT pathway. To do this task, we added the Dabrafenib species (at different concen-
trations, see Results section). Then we modeled two specific reactions i.e., the normal drug deg-
radation and the main effect of Dabrafenib in the inhibition of the bRafMutated species. From
the specific literature, it is reported that the half-life of Dabrafenib is 10 hours (European Medi-
cines Agency web site: http://www.ema.europa.eu). We used this parameter to set the associ-
ated mass action law to reproduce its decay.
Another important aspect not considered in Brown’s model is that all the receptors are very
rapidly triggered by EGF and consequently they remain constitutively activated because their
model did not take into account any reaction of degradation of receptors. We modeled this
aspect inserting a degradation process based on an irreversible mass action law affecting both
the free and bound RTK receptors. Moreover, the original Brown EGF model did not include
the C3G/Rap1 pathway, a fundamental key point for the activation of B-RAF and consequently
on ERK dynamics. To this end we modeled the activation of the C3G species through bound
RTK receptor, and the Rap1 activation through the activated C3G protein.
Furthermore, we deeply analyzed the fundamental role of AKT protein kinase in the cross-
talk between the two main pathways involved. In particular, we focused on the role of AKT on
the activation of mTORC1 pathway and on the activation/deactivation machinery of several
proteins on AKT signaling. The resulting implementation of the pathways model, along with
the relative set of ODEs can be found looking at the Figs 1 and 2.
Cell line culture and treatment
A375 cell line was obtained from ATCC (LGC Standards, Italy). This cell line derived from a
54 year old female with malignant melanoma and represents a good model for studying the
role of MAPK and AKT pathways because it is affected by the single alteration displayed in the
B-RAF gene (V600E) (See Cosmic web site, http://cancer.sanger.ac.uk/cosmic). In fact, the
presence of other genetic alterations, such as the mutations in KRAS or NRAS genes, may
determine the activation of MAPK pathway.
The A375 melanoma cell line, obtained from ATCC (LGC Standards, Italy), were cultured
in a humidified 5% CO2 incubator at 37°C with RPMI-1640 supplemented with 2 mmol/L L-
glutamine, 100 IU penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum (FBS), pur-
chased from LONZA (Walkersville, USA). The A375 were plated in 70 mm cell-culture dishes
at density of 500.000 cells and after 24h were treated for 48h with Dabrafenib (Selleck Chemi-
cal, USA) to final concentration of 2, 1, 0.5, 0.25 and 0.125 nM. Dimethyl Sulfoxide (DMSO)
(Sigma-Aldrich, USA) was used as control.
Western blot analysis
Protein profiling of treated A375 cell lines was analyzed by western blot using the Anti-MAP
Kinase ERK1/ERK2 (pThr202/ pThr204) rabbit Ab (cat. n. 442685) and Anti-MAP Kinase
ERK1/ERK2 rabbit Ab (cat. n. 442704) supplied fromMerck Millipore (Darmstadt, Germany)
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to detect phosphorylated and total ERK 1/2 proteins, respectively. The Anti-beta Tubulin Ab
(ab 15568- Abcam, Cambridge, UK) was used as housekeeping gene. Chromogenic detection
of proteins was performed with Novex HRP Chromogenic (Invitrogen, USA). Western blot
images were analyzed with image J software. All experiments were performed in triplicate. Stu-
dent's t-test was used for statistical analysis.
Results
We simulated our model under normal generic growth factor (GF) stimulation conditions to
verify that it gave a strong transient activation of ERK. Then we simulated the A375 cell line
with the B-RAF mutation. In this case, we expected elevated ERK activity that is characteristic
of B-RAFV600E mutated melanomas. Fig 3 shows the dynamics of both activated ERK (pERK)
and B-RAF. Left panel highlights the normal condition case; while, right panel shows B-RAF
mutated A375 cell line scenario. Finally, the simulation predicts correctly the expected behav-
ior i.e., the species ErkActive has a constant elevated activity. Due to the nonlinearities of the
presented model and to the high number of nodes and interactions inside the pathway, even if
there is a clear relationship between bRafActive and ErkActive, we cannot say that there is a
linear relationship between the two.
Fig 1. Diagram of PI3K-AKT andMAPK signaling pathways implemented into the model. Activation/deactivation reactions (modeled with a modified
Henri-Michaelis-Menten law) are shown in the following way: the modifier i.e., the catalyst that triggers the reaction is depicted by a thin light green line ending
with a rhombus; the involved species are connected by arrows starting with a blue color (input species) and ending with a brown color (resulting species). For
example, Raf1Inactive becomes activated (Raf1Active) through RasActive. Reactions that physiologically inactivate species (modeled with mass action law)
are depicted by an arrow starting with a blue color and ending with a brown color, for example C3G deactivation. Proteins degradation (modeled with mass
action law) are depicted with the considered species connected by an arrow ending with an empty set symbol, for example Dabrafenib degradation. Proteins
production (modeled with irreversible constant flux law) are depicted with the considered species connected by an arrow (for example, the production of free
RTK). The Arcadia software (http://arcadiapathways.sourceforge.net) has been used to produce the graphical representation of the model.
doi:10.1371/journal.pone.0152104.g001
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Fig 2. Complete list of the ordinary differential equations implemented in the model. The available versions of the Copasi models can be accessed as
S1 Archive.
doi:10.1371/journal.pone.0152104.g002
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In particular, higher levels of ErkActive are not observed probably due to the fact that
ErkActive is already near to its threshold levels and/or due to the contribution of other nodes
in the pathway that may influence the final outcome.
Moreover, we simulated the behavior of the A375 cell lines under different concentrations
of Dabrafenib inhibitor. B-RAF inhibition results in the limitation of pERK activity. Accord-
ingly, in Table 1 the percentage of the inhibition of pERK is shown as result of pERK and ERK
ratio. Concordant results were obtained analyzing in vitro and in silico data.
The dynamics of both pERK and B-RAF mutated were modeled (Fig 4). ERK in silico con-
centration was set to 600000 mmol/ml. Five panels are shown. Each panel depicts the pERK,
B-RAF mutated and Dabrafenib dynamics in 48 hours of simulation at different Dabrafenib
dosage i.e., 0.125 nM (A), 0.250 nM (B), 0.500 nM (C), 1.0 nM (D) and 2.0 nM (E). When no
treatment is administered (DMSO) pERK concentration reached 571950 mmol/ml at time 48
h. With different dosages of Dabrafenib, pERK concentrations reached 529602 mmol/ml (A),
368352 mmol/ml (B), 207518 mmol/ml (C), 106758 mmol/ml (D) and 53385 mmol/ml (E),
showing, respectively, the percentage of inhibition reported in Table 1.
The reduction of pERK concentrations is in agreement with that observed in vitro.
Fig 5 highlights western blotting plots. Also in this case, we obtained a good agreement with
the in silico results. In conclusion, both from the model results and from the in vivo experi-
ments, we can observe that p-ERK levels drop down due to inhibitor activity of Dabrafenib
over B-RAFV600E protein. We analyzed p-ERK as it is one of the key protein kinase involved
in cell proliferation signaling. An important aspect related to the inhibition of B-RAFV600E
Fig 3. pERK (ErkActive) and B-RAF dynamics. Left panel shows the behavior under normal GF stimulation while right panel depicts the dynamics with
B-RAF (bRafMutated) mutation in A375 cell lines.
doi:10.1371/journal.pone.0152104.g003
Table 1. pERK inhibition percentages in treated cell line.
Dabrafenib (nM) In vitro inhibition (%) In silico inhibition (%)
DMSO 100 100
0.125 84.3 93
0.250 60.1 64
0.500 38.1 36
1.0 19.2 19
2.0 16.7 9
Percentages of pERK inhibition are shown during different dosage treatment of B-RAF Dabrafenib inhibitor
in A375 cell line. DMSO represents the control case. The ratio is normalized taking as reference the DMSO
control values.
doi:10.1371/journal.pone.0152104.t001
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Fig 4. pERK, B-RAF and Dabrafenib in silico dynamics. pERK concentrations decrease during Dabrafenib treatment in A375 melanoma cell line. The
behavior of pERK is directly correlated to the Dabrafenib concentration. Different dosages of Dabrafenib are shown (1nM = 1e-9 mmol/ml): 1.25e-10 mmol/ml
(A), 2.5e-10 mmol/ml (B), 5e-10 mmol/ml (C), 1e-9 mmol/ml (D) and 2e-9 mmol/ml (E). In all the panels the right y-axis dotted lines represent bRafMutated
concentrations while solid lines represent Dabrafenib concentrations.
doi:10.1371/journal.pone.0152104.g004
Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
PLOS ONE | DOI:10.1371/journal.pone.0152104 March 25, 2016 8 / 10
protein is that a small fraction of treated melanoma patients develops resistance mechanisms
that make the therapy not more effective. The model can be useful to analyze the complex
PI3K/AKT and MAPK pathways in order to discover proteins that may cause these resistance
phenomena.
Conclusions
We presented a computational model that simulates both PI3K/AKT and MAPK pathways
and their interactions, in order to analyze the cascade reactions responsible for melanoma
development. We simulated a therapy intervention i.e., the administration of a well-known
B-RAF inhibitor, Dabrafenib. This study has shown how computational models can be useful
tools for investigating and comparing the biological behavior of signal transduction path- ways
as they can suggest new hypotheses to explain the observed biological data and help understand
the dynamics of how the pathway functions. Furthermore, computational models can be read-
ily used to investigate different disease states and suggest how drug treatment could be
improved to better combat the effects of the disease. We believe that our model is a good repre-
sentation of the PI3K/AKT and MAPK with activated ERK pathway which can be expanded
and applied in the future to further investigate the dynamics of resistant mechanisms in order
to suggest new intervention to suggest new therapeutical interventions.
Supporting Information
S1 Archive. In the zip archive, there are three different available versions of the model: File
PI3K_AKT_Final_V2.1.cps, physiological model i.e., no B-RAF mutation; File
PI3K_AKT_Final_V2.1_A375.cps, A375 cell line model i.e, with B-RAF mutation; File
PI3K_AKT_Final_V2.1_A375_Dabrafenib.cps, complete model with both B-RAF muta-
tion and Dabrafenib inhibitor set at the lower dosage.
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Fig 5. Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK
signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.
doi:10.1371/journal.pone.0152104.g005
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